Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . 華潤 醫藥 集團 有限公司 China Resources Pharmaceutical Group Limited ( Incorporated in Hong Kong with limited liability ) ( Stock Code : 3320 ) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026 The board ( the " Board " ) of directors ( the “ Directors " ) of China Resources Pharmaceutical Group Limited ( the “ Company ” or “ China Resources Pharmaceutical ” ) is pleased to announce the unaudited condensed consolidated interim results of the Company and its subsidiaries ( the “ Group ” ) for the six months ended 30 June 2026 ( the “ Reporting Period ” ) , together with the comparative figures for the previous year / period as follows : CONSOLIDATED STATEMENT OF PROFIT OR LOSS For the six months ended 30 June 2026 - unaudited ( Expressed in Renminbi ( " RMB " ) ) Note Revenue Cost of sales Gross profit Other income Other gains and losses Selling and distribution expenses Administrative expenses Other expenses , net Finance income Six months ended 30 June 2026 RMB'000 2025 RMB'000 134,457,581 131,866,817 ( 112,923,458 ) ( 110,357,203 ) 21,534,123 21,509,614 5 6 850,264 ( 710,065 ) 849,442 ( 1,086,255 ) ( 10,145,719 ) ( 10,010,130 ) ( 3,344,477 ) ( 3,186,557 ) ( 1,164,836 ) ( 1,038,382 ) 200,462 271,275 Finance costs ( 909,064 ) ( 1,006,278 ) Finance costs , net 7 ( 708,602 ) ( 735,003 ) − 1 −